Search Results

evidence. 16 Long-term outcomes of both neoadjuvant and adjuvant therapy and local excision need to be confirmed by large prospective randomized trials. Currently, the Dutch national guidelines consider these treatments experimental and state that these

adjuvant treatment to improve outcomes, and several trials have evaluated escalation of adjuvant therapy. 16 – 18 The recently published CREATE-X trial 19 evaluated 910 patients with HER2-negative breast cancer who had residual invasive disease or LN

-free survival, there was clear benefit for nivolumab as adjuvant therapy (22.4 vs 11.0 months; HR, 0.69; P =.0003), with the benefit sustained over time. Nivolumab was favored in all subgroups. “This is the most robust data we have seen showing any benefit

neoadjuvant arm. 7 The neoadjuvant arm involved administering oxaliplatin and fluorouracil or capecitabine for 6 weeks, followed by surgery, and then up to a perioperative total of 3 versus 6 months of adjuvant therapy. This trial revealed that patients with

NCCN Guidelines now list osimertinib as an option for adjuvant therapy in patients with resectable stage IIB–IIIA or high-risk stage IB–IIA NSCLC harboring EGFR mutations who received previous adjuvant chemotherapy or are ineligible to receive

tumor specimens of patients enrolled in randomized studies of adjuvant 5-fluorouracil with levamisole or leucovorin compared with no adjuvant therapy. 98 This study showed no improvement in overall survival in patients with stage II and III colon cancer

and the decreasing likelihood of receiving neoadjuvant/adjuvant therapy. 42 , 43 , 47 A reason for these findings has been the increasing prevalence of comorbid disease in older age groups. Consistent with the literature, 10 , 38 , 42 , 43 , 47 – 52

individually been evaluated in the neoadjuvant and adjuvant settings with mixed results. 74 – 77 At this time, the guidelines of the AASLD and the European Association for the Study of the Liver do not recommend neoadjuvant or adjuvant therapy in most patients

toxicity calculator, then they may opt for surgical resection and discussion of the role of adjuvant therapy based on the pathologic risk identified at the time of surgery. Table 2. Criteria for Cisplatin Ineligibility For patients who do not receive NAC

relative importance of chemotherapy and radiation as adjuvant therapy ( Table 1 ). The ESPAC-1 trial, 2 conducted by the European Study Group for Pancreatic Cancer, used a 2-by-2 factorial design in which patients were randomly assigned after surgery to 1